Although GLP-1 receptor agonists improve mortality in low-risk patients, the absolute benefits are very small
Does this new weight-loss drug work better than Wegovy and Ozempic
the lowest effective maintenance dose is generally preferred
Researchers often account for this by using sufficiently large sample sizes and proper randomization techniques
Dont miss this rapid-fire, 25minute panel in the Opening General Session at ODAC 2026 (Jan 16): GLP1 Agonists in Cutaneous Medicine: RapidFire Insights on Comorbidities, Safety, and Aesthetic Considerations Moderator: Adam Friedman, MD, FAAD Panelists: Jennifer Soung, MD, FAAD
It may not be flashy, but its simplicity, quality sourcing, and flexibility make it a standout for those who value what goes into their shake as much as what they get out of it